Related Experiment Video
Updated: May 21, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
NOS-2 signaling and cancer therapy
Ka Bian1, Farshid Ghassemi, Alex Sotolongo
1Department of Biochemistry and Molecular Biology, George Washington University, School of Medicine, Washington, DC, USA. bcmfxm@gwu.edu
Nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) signaling roles in cancer remain unclear. Targeting inducible nitric-oxide synthase (iNOS) and normalizing sGC-cGMP pathways may offer novel cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) signaling pathway's role in tumor biology is complex and debated.
- High concentrations of NO, produced by inducible nitric-oxide synthase (iNOS or NOS-2), can be cytotoxic or apoptotic, while its signaling functions vary by cell type and tissue.
- Tumors comprise neoplastic cells (parenchyma) and supporting nonmalignant tissues (stroma), each with distinct NO biology.
Purpose of the Study:
- To review the expression of NOS-2 in tumor and surrounding cells.
- To summarize research outcomes regarding the NO/sGC/cGMP pathway in cancer therapy.
- To propose therapeutic strategies targeting this signaling axis.
Main Methods:
- Literature review focusing on NOS-2 expression in tumor microenvironments.
- Analysis of existing research on the NO/sGC/cGMP pathway in cancer.
- Synthesis of findings to evaluate therapeutic potential.
Main Results:
- NOS-2 expression varies significantly between tumor cells and the tumor microenvironment.
- The dual role of NO (cytotoxic vs. signaling) contributes to the ambiguity surrounding its impact on cancer.
- The NO/sGC/cGMP pathway's components and functions differ across various cellular compartments within tumors.
Conclusions:
- A normally functioning soluble guanylate cyclase (sGC)-cGMP signaling axis may be crucial for preventing and treating malignant tumors.
- Inhibiting iNOS overexpression and the tumor inflammatory microenvironment, alongside normalizing sGC/cGMP signaling, presents a potential alternative to conventional cancer treatments.
- Further characterization of NO/sGC/cGMP signaling in both tumors and surrounding tissues is essential for developing targeted therapies.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Non-Canonical Wnt Signaling Pathways
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...